Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients

Abdel-Moneim, Adel; Aboud, Alaa; Abdel‐Gabbar, Mohammed; Zanaty, Mohamed I.; Ramadan, Mohamed

doi:10.1007/s10620-018-5005-8

Cited by 13 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study showed no significant difference in SVR12 rates achieved by noncirrhotic patients (96.8%) and that achieved by cirrhotic patients (100%), which was in accordance with other studies by Abdel‐Moneim and colleagues 25,27 . In patients who used SOF/DAC/SMV/RBV, the SVR12 rates were 91% and 99% in cirrhotic and noncirrhotic patients, respectively.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Yousif

Ahmed

Elsadek

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

“…In SOF/OBV/PTV/r + RBV group, SVR12 rates were 98.8%. Similar results were published by Abdel‐Moneim et al 27 who retreated 113 Egyptian CHC patients who failed to respond to prior DAA therapy, by SOF/OBV/PTV/r/RBV for 12 weeks. SVR12 was achieved in 109 patients (97%).…”

Section: Discussionsupporting

confidence: 86%

Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Yousif

Ahmed

Elsadek

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…The regimen is effective with non-approved triple combinations such as sofosbuvir, daclatasvir, simeprevir plus ribavirin or sofosbuvir with grazoprevir and elbasvir plus ribavirin. These regimens may be useful in regions in which triple therapy is not available 89–91 . Moreover, preliminary data from a phase 3b study evaluating glecaprevir and pibrentasvir treatment of patients with HCV genotype 1 infection failed by an NS5A inhibitor and sofosbuvir (with or without ribavirin) indicated that 95% of patients maintained an SVR for 4 weeks after treatment.…”

Section: Treatment Of Patients Failed By Daasmentioning

confidence: 99%

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges

et al. 2019

View full text Add to dashboard Cite

Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. Following the discovery of HCV 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized care of patients, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for HCV infection and discuss remaining challenges. We highlight licensed compounds, discuss the potential to shorten therapy even further, and review different options for treatment failure and resistance. We also provide an overview on clinical experience with generic agents and evidence for their efficacy. Finally, we discuss the need for new drugs and outline promising targets for future therapies.

show abstract

“…Despite this, levels of HBV DNA and HBeAg clearance for CHM formula granules were much lower than for antivirals [50] or interferon [51]. This is a similar finding for patients with HCV RNA and HCV RNA clearance levels for CHM formula granules were much lower than for antivirals [52].…”

Section: Discussionmentioning

confidence: 74%

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Han

Lai

Li³

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To summarize the characteristics and the outcomes of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Granules manufactured by China Resources Sanjiu Pharmaceutical Co., Ltd. Methods. Databases including China National Knowledge Infrastructure, VIP, Wanfang, PubMed, Cochrane Library, and clinicaltrials.gov were searched in March 2018 for relevant randomized controlled trials (RCTs). Two reviewers independently screened for and selected studies, extracted data, and checked data extraction. Methodological quality was evaluated using the Cochrane Risk of Bias tool. For the outcome, the characteristics of the study, the cure rate, the effectiveness rate, and advert events were described with a method of bibliometrics. Also, we performed meta-analysis only if there were ≥2 studies treated by the same intervention and evaluated by the same outcome. Results. A total of 40 placebo-controlled RCTs treated for 17 diseases were included in our analysis involving 4,632 patients. 16 of 19 studies treated by CHM granules only showed positive result in patients with HBV, HCV, fever, depression, nonalcoholic fatty liver disease, AIDS, and asthma while negative result was shown in patients with migraine. 17 of 21 studies treated by combination therapy against conventional therapy showed positive result in patients with HBV, herpes simplex keratitis, COPD, liver cirrhotic ascites, Parkinson’s disease, and diabetic peripheral neuropathy while negative result was shown in patients with myasthenia gravis, angina pectoris, and depression. The pooled result cannot demonstrate that the notifying kidney formula granules had the superior effect with placebo on the clearance of serum HBV DNA and HBeAg in HBV carriers with a RR (and the 95% CI) of 2.97 [0.74,11.91] and 1.99 [0.93,4.29], respectively. But, the CHM granules can reduce within-group HBV DNA levels by more than 2 lgIU/ml; the RR (and 95% CI) was 4.64 [2.89,7.45]. Qizhu granules had a significant effect on clearance of HCV RNA with a RR (and 95% CI) of 6.26 [2.16,18.16]. And, the heat-clearing and detoxifying formula granules were superior to placebo in resolution of cold symptom among patients with fever with a RR and 95% CI of 2.58 [1.40,4.74]. Based on the conventional therapy, the pooled result demonstrated that the Regulating liver formula granules were superior to placebo on the clearance of serum HBeAg in chronic hepatitis B patients with a RR (and the 95% CI) of 1.73 [1.30,2.31]. The EeChen decoction granules were superior to placebo in COPD patients with a RR (and the 95% CI) of 1.13 [1.06,1.22]. 28 of the 40 studies reported adverse events. There were 51 adverse events in CHM formula granules group or combination group (n=2,483) and 26 in control group (n=2,122) totally. Most of the adverse symptoms spontaneously resolved after completing the courses of treatment and the other adverse symptoms improved after symptomatic treatment. Conclusion. 16 of 19 studies treated by CHM granules only showed positive result in 7 diseases and negative result in 1 disease. 17 of 21 studies treated by combination therapy against conventional therapy showed positive result in 6 diseases and negative result in 3 diseases. However, both the absolute and relative effectiveness of CHM formula granules compared with placebo need to be considered clinically.

show abstract

Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients

Cited by 13 publications

References 21 publications

Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Contact Info

Product

Resources

About